Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2775240 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2775240 (Part A) | EXPERIMENTAL | Escalating oral doses of LY2775240 administered in healthy participants |
| LY2775240 (Part B) | EXPERIMENTAL | Oral dose of LY2775240 in healthy participants |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered orally in healthy participants |
| Apremilast (Part B) | ACTIVE_COMPARATOR | Oral dose of apremilast in healthy participants |
| Name | Type | Description |
|---|---|---|
| LY2775240 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| Apremilast | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy adult male or a female who cannot get pregnant * Have a screening body mass index (BMI) of greater than 18 and less than or equal to 32 kilograms per meter square (kg/m²), inclusive * Have normal blood pressure, pulse rate, electrocardiogram (ECG) and medical t...
LY2775240 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other. As of now, it is not approved and remains in clinical trials.
LY2775240 is being studied for use in healthy participants. It is an investigational small molecule in Phase 1 clinical development. The drug has not been approved for any medical condition, and its current trials focus on assessing its effects in healthy volunteers rather than treating a specific disease.
LY2775240 is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development and has been studied in healthy participants.
LY2775240 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug has completed one Phase 1 trial in healthy participants, and no active trials are currently listed.
LY2775240 has been studied in one clinical trial, identified as NCT02963779, titled "A Study of LY2775240 in Healthy Participants." This Phase 1 trial was completed and enrolled 35 participants in Singapore. The trial was randomized, double-blind, and placebo-controlled, involving healthy volunteers aged 21 years and older.